Pictet Asset Management (Switzerland)’s Coherus Oncology CHRS Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$6.1M	Buy	1,428,188 +573,930	+67%	+$3.39M	0.01%	730
2023 Q1	$5.84M	Buy	854,258 +544,306	+176%	+$4.22M	0.01%	752
2022 Q4	$2.46M	Buy	309,952 +78,160	+34%	+$601K	﹤0.01%	895
2022 Q3	$2.23M	Buy	231,792 +63,964	+38%	+$647K	﹤0.01%	907
2022 Q2	$1.22M	Buy	167,828 +43,889	+35%	+$382K	﹤0.01%	1022
2022 Q1	$1.6M	Sell	123,939 -34,636	-22%	-$440K	﹤0.01%	994
2021 Q4	$2.53M	Hold	158,575	–	–	﹤0.01%	966
2021 Q3	$2.55M	Buy	+158,575	New	+$2.32M	﹤0.01%	957

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s CHRS Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) increased its Coherus Oncology (CHRS) stake by 67% in Q2 2023, buying an estimated $3.39M and bringing the position to 1,428,188 shares worth $6.1M. The position accounts for 0.01% of the portfolio, ranked #730.

Pictet Asset Management (Switzerland) first reported a position in CHRS in Q3 2021 and has held it in 8 quarters since. 161 funds tracked by Wall St. Rank hold CHRS as of Q2 2023.

Pictet Asset Management (Switzerland) held 1,428,188 shares of Coherus Oncology worth $6.1M as of Q2 2023.
Pictet Asset Management (Switzerland) bought 573,930 Coherus Oncology shares in Q2 2023, an estimated $3.39M.
Coherus Oncology made up 0.01% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #730 holding.
Pictet Asset Management (Switzerland) first reported a position in Coherus Oncology in Q3 2021 and has held it in 8 quarters since.
161 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.